April 14 (Reuters) - Schrodinger Inc SDGR.O:
SCHRÖDINGER’S STATEMENT REGARDING FDA PLAN TO PHASE OUT ANIMAL TESTING REQUIREMENT FOR MONOCLONAL ANTIBODIES AND OTHER DRUGS
SCHRODINGER INC - SCHRÖDINGER SUPPORTS FDA PLAN TO REDUCE ANIMAL TESTING REQUIREMENTS
SCHRODINGER INC - PREDICTIVE TOXICOLOGY SOLUTION EXPECTED TO LAUNCH IN H2 2025
Source text: ID:nBw6Frfx6a
Further company coverage: SDGR.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.